Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension of Burosumab in XLH
NCT04308096Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of burosumab in X-linked hypophosphatemia (XLH), sponsored by Kyowa Kirin. Started Jan 2018; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT04308096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308096.